Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DLB and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DLB and 80,000+ other tickers.
See exactly how DLB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DLB and 80,000+ other tickers.
Dolby Laboratories, Inc. develops pioneering audio and visual technologies designed to enhance entertainment and communication experiences across a broad spectrum of platforms. These include cinematic venues, digital television, various transmission and playback devices, mobile communications, online streaming video and music platforms, and home entertainment systems. The company is actively involved in inventing and licensing its advanced sound technologies. This portfolio features solutions like AAC & HE-AAC, a digital audio codec widely adopted for diverse media applications; AVC, a…
Dolby Laboratories is now undervalued after a 50%+ decline from its all-time high, trading at 18.7x FCF and 19.7x earnings. DLB's revenue growth remains choppy, but licensing—especially in Broadcast and Mobile—drives solid results and offers mid-single-digit growth potential. Expansion into automotive and increased adoption of Dolby Atmos/Vision by major platforms and automakers support future growth, with modest price increases feasible.
SAN FRANCISCO, July 14, 2026 /PRNewswire/ -- Dolby Laboratories, Inc. (NYSE: DLB), a leader in immersive entertainment experiences, will release financial results for the third quarter (Q3) fiscal year 2026 after the close of regular trading on Thursday, July 30, 2026. Members of Dolby management will lead a conference call open to all interested parties to discuss Q3 fiscal year 2026 financial results for Dolby Laboratories at 2:00 p.m.
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -